Deirdre Gillespie
Directeur Général chez IRAD Oncology, Inc.
Profil
Deirdre Y.
Gillespie currently works at IRAD Oncology, Inc., as Chief Executive Officer from 2013.
Dr. Gillespie also formerly worked at La Jolla Pharmaceutical Co., as President, Chief Executive Officer & Director from 2011 to 2012, Oxxon Therapeutics, Inc., as President & Chief Executive Officer from 2001 to 2005, Virttu Biologics Ltd., as Chief Executive Officer, Apricus Biosciences, Inc., as Independent Director from 2010 to 2016, Vical, Inc., as Chief Operating Officer from 1998 to 2001, and DuPont Merck Pharmaceutical Co., as Vice President-Marketing from 1991 to 1996.
Dr. Gillespie received her undergraduate degree and doctorate degree from the University of London and Masters Business Admin degree from London Business School.
Postes actifs de Deirdre Gillespie
| Sociétés | Poste | Début |
|---|---|---|
| IRAD Oncology, Inc. | Directeur Général | 01/01/2013 |
Anciens postes connus de Deirdre Gillespie
| Sociétés | Poste | Fin |
|---|---|---|
Apricus Biosciences, Inc.
 Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 05/04/2016 |
| LA JOLLA PHARMACEUTICAL COMPANY | Directeur Général | 19/01/2012 |
Oxxon Therapeutics, Inc.
 Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | President | 01/01/2005 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Directeur des opérations | 01/01/2001 |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Sales & Marketing | 01/01/1996 |
Formation de Deirdre Gillespie
| University of London | Doctorate Degree |
| London Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Oxxon Therapeutics, Inc.
Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Health Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
| IRAD Oncology, Inc. | |
Virttu Biologics Ltd.
 Virttu Biologics Ltd. Pharmaceuticals: OtherHealth Technology Virttu Biologics Ltd. operates as a biopharmaceutical company. It develops oncolytic virus therapy for treatment of cancer. The firm's product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient. The company is headquartered in Glasgow, the United Kingdom. | Health Technology |
